AN ACUTE MYELOID-LEUKEMIA GENE, AML1, REGULATES HEMATOPOIETIC MYELOID CELL-DIFFERENTIATION AND TRANSCRIPTIONAL ACTIVATION ANTAGONISTICALLY BY 2 ALTERNATIVE SPLICED FORMS

被引:207
作者
TANAKA, T
TANAKA, K
OGAWA, S
KUROKAWA, M
MITANI, K
NISHIDA, J
SHIBATA, Y
YAZAKI, Y
HIRAI, H
机构
[1] UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN
[2] UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,BUNKYO KU,TOKYO 113,JAPAN
[3] JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
关键词
ALTERNATIVE SPLICING; AML1; ANTAGONISTIC ACTION; MYELOID DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION;
D O I
10.1002/j.1460-2075.1995.tb07008.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The AML1 gene on chromosome 21 is disrupted in the (8;21)(q22;q22) and (3;21)(q26;q22) translocations associated with myelogenous leukemias and encodes a DNA binding protein. From the AML1 gene, two representative forms of proteins, AML1a and AML1b, are produced by alternative splicing, Both forms have a DNA binding domain but, unlike AML1b, AML1a lacks a putative transcriptional activation domain, Here we demonstrate that overexpressed AML1a totally suppresses granulocytic differentiation and stimulates cell proliferation in 32Dcl3 murine myeloid cells treated with granulocyte colony-stimulating factor, These effects off AML1a were canceled by the concomitant overexpression of AML1b, Such biological phenomena could be explained by our observations that (i) AML1a, which on its own has no effects as a transcriptional regulator, dominantly suppresses transcriptional activation by AML1b, and (ii) AML1a exhibits the higher affinity for DNA binding compared with AML1b. These antagonistic actions could be important in leukemogenesis and/or myeloid cell differentiation because more than half of myelogenous leukemia patients showed an increase in the relative amounts of AML1a.
引用
收藏
页码:341 / 350
页数:10
相关论文
共 58 条
  • [41] 2 DIFFERENT FACTORS BIND TO THE ALPHA-DOMAIN OF THE POLYOMA-VIRUS ENHANCER, ONE OF WHICH ALSO INTERACTS WITH THE SV40 AND C-FOS ENHANCERS
    PIETTE, J
    YANIV, M
    [J]. EMBO JOURNAL, 1987, 6 (05) : 1331 - 1337
  • [42] INDISTINGUISHABLE NUCLEAR FACTOR BINDING TO FUNCTIONAL CORE SITES OF THE T-CELL RECEPTOR DELTA AND MURINE LEUKEMIA-VIRUS ENHANCERS
    REDONDO, JM
    PFOHL, JL
    HERNANDEZMUNAIN, C
    WANG, SW
    SPECK, NA
    KRANGEL, MS
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (11) : 4817 - 4823
  • [43] RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1531
  • [44] A DOMINANT NEGATIVE FORM OF TRANSCRIPTION ACTIVATOR MTFE3 CREATED BY DIFFERENTIAL SPLICING
    ROMAN, C
    COHN, L
    CALAME, K
    [J]. SCIENCE, 1991, 254 (5028) : 94 - 97
  • [45] ROVERA G, 1987, ONCOGENE, V1, P29
  • [46] Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19
  • [47] GAL4-VP16 IS AN UNUSUALLY POTENT TRANSCRIPTIONAL ACTIVATOR
    SADOWSKI, I
    MA, J
    TRIEZENBERG, S
    PTASHNE, M
    [J]. NATURE, 1988, 335 (6190) : 563 - 564
  • [48] Sambrook J., 1989, MOL CLONING
  • [49] DIFFERENTIAL EXPRESSION OF SUBSPECIES OF POLYOMAVIRUS AND MURINE LEUKEMIA-VIRUS ENHANCER CORE BINDING-PROTEIN, PEBP2, IN VARIOUS HEMATOPOIETIC-CELLS
    SATAKE, M
    INUZUKA, M
    SHIGESADA, K
    OIKAWA, T
    ITO, Y
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (07): : 714 - 722
  • [50] SATAKE M, 1988, ONCOGENE, V3, P69